Drugs / Certolizumab
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03293784 | Oct 2017 → Dec 2019 | melanoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 1 | NCT02120807 | Apr 2014 → Jan 2023 | lung adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06028438 | Aug 2023 → Aug 2024 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04991025 | Oct 2022 → Oct 2026 expected | lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05930613 | Nov 2023 → Apr 2029 expected | infertility disorder | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05379322 | Mar 2023 | rheumatoid arthritis | Abu Dhabi Stem Cells Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT02779114 | Jan 2009 → Dec 2017 | rheumatoid arthritis | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05080218 | Nov 2021 → Apr 2024 | psoriatic arthritis, spondyloarthropathy | Jeffrey Curtis | Completed | No outcome recorded |
| Phase 4 | NCT02714634 | Mar 2016 → Mar 2029 expected | rheumatoid arthritis | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 4 | NCT02132234 | Jun 2013 → Jul 2014 | ankylosing spondylitis, hypertensive disorder, psoriatic arthritis | Jagiellonian University | Unknown | No outcome recorded |
| Phase 4 | NCT01602302 | Jun 2012 → Nov 2020 | rheumatoid arthritis | Medical University of Graz | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05305066 | Feb 2023 → Dec 2028 expected | rheumatoid arthritis | Marie Hudson, MD | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02862574 Background | Dec 2016 → Jun 2017 | rheumatoid arthritis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03414502 Comparator | Dec 2007 → Mar 2028 expected | rheumatoid arthritis | University of Nebraska | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03445845 Comparator | Dec 2018 → Sep 2024 | spondyloarthropathy | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 4 | NCT02242474 Comparator | Jul 2015 → Oct 2019 | rheumatoid arthritis | CHU de Quebec-Universite Laval | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-11-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results of two trials show a rapid and sustained response with certolizumab pegol for treatment of rheumatoid arthritis (J-RAPID and HIKARI Studies) released at 2011 meeting of American College of Rheumatology (ACR) otsuka.co.jp ↗ |
| 2008-06-10 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and UCB agreed to co-develop and co-promote Keppra and Cimzia in Japan®® otsuka.co.jp ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Certolizumab | “certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks” NCT05305066 ↗17“An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.” NCT02862574 ↗ “certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections” NCT03445845 ↗ “Adalimumab, etanercept, certolizumab, or golimumab” NCT05379322 ↗ “Methotrexate or leflunomide + certolizumab or” NCT02714634 ↗ “Certolizumab (Cimzia®)” NCT02779114 ↗ “Certolizumab” NCT05080218 ↗ “Certolizumab” NCT02242474 ↗ |
| Known as | CIMZIA | “Certolizumab (CIMZIA® ; TNF-α antagonist)” NCT05930613 ↗1“Certolizumab (Cimzia®)” NCT02779114 ↗ |
| Action | Inhibit | “Nivolumab+Ipilimumab administered in combination with the anti-TNF-α either Infliximab or Certolizumab” NCT03293784 ↗ |
| Modality | Protein / enzyme biologic | “Certolizumab is a fusion between a fab fragment targeting TNF and a Peg fraction” NCT03445845 ↗ |
| Route | Subcutaneous | “* certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks” NCT02132234 ↗ |
| Target | TNF | “Nivolumab+Ipilimumab administered in combination with the anti-TNF-α either Infliximab or Certolizumab” NCT03293784 ↗ |